Cell
Volume 184, Issue 6, 18 March 2021, Page 1401
Journal home page for Cell

Bench to Bedside
Messenger RNA vaccines against SARS-CoV-2

https://doi.org/10.1016/j.cell.2020.12.039Get rights and content
Under an Elsevier user license
open archive

Summary

The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF.

Cited by (0)